Neurology Treatment Success Rates in Switzerland
Reviewed by the SwissAtlas coordination team · Last updated:
Evidence preparation before neurological review guides the way families prepare high-stakes decisions under cross-border pressure.
Reviewed by the SwissAtlas coordination team · Last updated:
Evidence preparation before neurological review guides the way families prepare high-stakes decisions under cross-border pressure.
Neurological treatment outcomes vary more by indication and candidate selection than by institution. A Gamma Knife local control rate of 90% for meningioma and a DBS motor improvement rate of 60–70% for Parkinson disease reflect very different clinical realities and cannot be compared as quality indicators. Families should always request outcome data filtered to the specific indication, staging or severity grade, and intervention type that applies to their case — not programme-level averages that aggregate across very different patient populations.
Neurological treatment coordination in Switzerland is aligned with standards maintained by the Swiss Neurological Society.
SwissAtlas supports international families navigating complex medical situations with discretion and clarity. Each case is handled with strict confidentiality and a structured coordination approach. Designed for sensitive situations requiring discretion and clarity.
Local tumour control rates for Gamma Knife radiosurgery are well-documented across primary indications. Vestibular schwannoma control at five years in appropriately selected cases is consistently reported at 90–95% in high-volume centres. Meningioma control at five years for WHO grade I lesions falls in the 85–95% range. Brain metastasis local control at 12 months varies by size, number, and primary histology, with single-fraction radiosurgery for smaller lesions (below 2 cm) achieving 80–90% local control in favourable cases.
Trigeminal neuralgia pain response to Gamma Knife is reported as initial adequate response in 70–90% of patients, with sustained response at three years in approximately 50–60%. Families should note that response rates decline over time and that repeat radiosurgery is sometimes required. Discussing realistic long-term outcome expectations at first consultation — not just initial response rates — is important for informed consent.
DBS motor outcomes in Parkinson disease are typically reported as percentage improvement in UPDRS-III (motor scale) scores in the off-medication state. Well-selected candidates at experienced Swiss centres commonly achieve 50–70% motor improvement. Tremor control is generally the most robust outcome; axial symptoms — gait, balance, speech — respond less reliably. Families should request specific outcome data for the dominant symptom cluster relevant to their case rather than relying on aggregate motor improvement scores.
DBS for treatment-resistant depression is an emerging indication with less established outcome data than movement disorder applications. Success rates vary significantly across protocols and patient selection criteria, and families considering this indication should approach outcome claims with particular scrutiny, requesting published data from the specific programme rather than general literature benchmarks.
Epilepsy surgery outcomes are most meaningfully expressed using the Engel classification: Class I (worthwhile improvement, predominantly seizure-free) represents the strongest outcome, with rates varying by syndrome and resection type. Temporal lobe resection for mesial temporal sclerosis achieves Class I outcomes in 60–80% of appropriately selected patients at experienced centres. Extratemporal resections generally have lower success rates due to the greater difficulty of precise localisation outside the temporal lobe. Families should request Engel class distribution data rather than binary "seizure-free" percentages, which can mask important gradations in outcome quality.
SwissAtlas operates exclusively as a non-medical coordination platform. We do not provide clinical services, diagnoses, or treatment recommendations. All medical decisions are made by licensed Swiss institutions.
Gamma Knife local control rates by indication: meningioma grade I 90–95% at five years; acoustic neuroma 93–97% with 70% hearing preservation; single brain metastases below 3cm 85–90% at one year; AVM obliteration 80–85% at two to three years. DBS for Parkinson's disease produces approximately 50% improvement on UPDRS motor score at one year in appropriately selected patients; best outcomes correlate with levodopa response above 30% and absence of significant cognitive impairment. Epilepsy surgery in temporal mesial sclerosis achieves seizure freedom in approximately 60–70% of cases at two years.
Volume-outcome relationships are significant in neurosurgery. Centres performing more than 50 complex glioma resections per year consistently show lower complication rates than lower-volume units. This is a meaningful criterion when evaluating institutional options for surgical neurological cases.
Neurological outcome data is more heterogeneous than cardiac data because the range of conditions and interventions is far wider, and because functional outcomes — cognitive preservation, seizure freedom, motor improvement — are harder to standardise than procedural mortality. Families should interpret published figures as order-of-magnitude benchmarks, not guarantees, and focus the conversation with institutions on how their specific case profile maps to the published cohorts.
For brain tumour surgery, the relevant outcome metrics are extent of resection, neurological deficit rate, and time to adjuvant treatment. For epilepsy surgery, the Engel classification is the standard — Engel I (seizure freedom or rare auras) is the target outcome; Engel II-III (meaningful reduction) is a secondary outcome. Ask the institution what proportion of their recent temporal lobe epilepsy cases achieved Engel I at two-year follow-up — this is a specific enough question to be meaningful.
For radiosurgery (Gamma Knife), local control is well-defined and consistently reported, making centre comparison more reliable. Families can reasonably compare tumour-type-specific local control rates across major Gamma Knife centres. Where there is more variability is in cranial nerve preservation rates for acoustic neuroma — this outcome is technique-sensitive and centre-volume-sensitive in a way that local control is not. It is the most informative single question for acoustic neuroma families evaluating Gamma Knife options.
SwissAtlas presents institutional quality questions — tumour board structure, surgical volume, trial access — to families at the file review stage, before an institutional introduction is made. This ensures that the introduction is targeted to the institution whose quality profile matches the case requirements, rather than to the most recognised name.
SwissAtlas coordinates non-clinical sequencing, documentation flow, and logistics governance while licensed institutions retain medical decision authority.
Records should be assembled as chronology with unresolved questions so specialist review can proceed without avoidable interpretation gaps.
Budgets should be scenario-based because pathway scope can evolve after deeper institutional evidence review.
Confidentiality is strengthened by role-based recipient controls and approved channels defined before high-sensitivity updates begin.
Timelines are safer when logistics commitments are tied to confirmed milestones rather than assumptions made before candidacy is established.
Confidential access to private medical care in Switzerland.
SwissAtlas operates at the intersection of discretion, structure, and access. Unlike traditional intermediaries, we do not promote specific clinics or treatments. Our role is to provide a neutral, structured, and confidential coordination layer for international patients navigating complex medical situations. This approach allows families to move forward with clarity, without pressure, and without exposure.
SwissAtlas is designed for: international families seeking discretion; patients requiring fast and structured access; situations where clarity and confidentiality are essential.
No medical advice. No pressure. Only structured coordination.
For full pathway context, review Neurology Treatment Switzerland, and also see the main treatment page.
For the complete strategic framework, review medical travel in Switzerland, treatment in Switzerland for international patients, and private healthcare Switzerland.